Compared to female breast cancer (FBC), MBC shows a higher prevalence of hormone receptor positivity and distinct germline predispositions, most frequently pathogenic variants in <i>BRCA2</i> and <i>CHEK2</i>. This evidence concerns the gene CHEK2 and complete blood cell count.